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Abstract 
Haematuria has a prevalence of 0.1% - 2.6%. Potential diagnoses may include infection, 
kidney stones, trauma, exercise or spurious causes, such as foods, drugs or menstruation, 
and a tumour. Approximately 40% of patients with haematuria are found to have a 
significant underlying pathology, with half of these having a urological malignancy. 
Haematuria is subsequently known as the “classic presentation” of bladder cancerwith 70 - 
80% of patients experiencing painless, gross (visible) haematuria.  However, in all cases of 
visible haematuria, a tumour should be suspected until proven otherwise.  
 
A  patient with visible haematuria requires urgent, stringent investigation warranting 
specialist assessment and subsequent selective referral through a series of patient centred 
investigations at a Haematuria clinic. One-stop clinics have shown to improve the patient 
experience in early diagnosis of potentially life threatening conditions although such clinics 
are less common in Urology settings, despite morbidity and mortality from bladder cancer 
increasing. This paper will discuss the tests and investigations that need to be undertaken in 
an individual with either visible or non-visible haematuria, and outline the care that is 
needed to support patients through the investigation process.  
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Introduction 
Blood in the urine, known as haematuria, is classified as microscopic or macroscopic, or 
more recently, (based upon joint guidelines from the Renal Association and the British 
Association of Urological Surgeons) visible haematuria (VT) and non-visible haematuria 
(NVH) (BAUS/RA, 2007; Lotan, et al,2009) and can indicate significant underlying disease. In 
visible haematuria, which has also been referred to as gross haematuria, urine is coloured 
pink or red and is reported by the patient or seen by the healthcare practitioner during 
urinalysis. Non-visible haematuria has also been referred to as dipstick-positive haematuria, 
is subdivided into symptomatic NVH (where the symptoms include urinary hesitancy, 
urgency or dysuria) and asymptomatic NVH (where detection is incidental and in the 
absence of symptoms). 
Haematuria is a common urological condition, occurring in up to 10-20% of individuals, 
presenting in any age group, and accounting for up to 20% of Urology referrals (Miah and 
Catto, 2010). Causes of haematuria vary by age, gender, ethnic group, duration or a 
combination of these (Ng, et al.2012). Irrespective of the cause, haematuria requires 
investigation due to its potential to indicate malignancy. Although haematuria is not always 
a herald of malignancy (Watkins, 2007), between 85 - 90% of patients that present with 
painless haematuria have a tumour of the urinary tract.  
Transient causes of haematuria, for example urinary tract infection (UTI), exercise induced 
haematuria and menstruation, need to be excluded before the extent of the severity of 
haematuria can be established (Henning, et al. 2013). Vigorous exercise, for example long-
distance running and swimming, can cause transient haematuria that usually resolves within 
24-48 hours (Rees, et al. 2008). Women are at greater risk than men of experiencing 
haematuria, as they are more likely to develop UTI, for example cystitis, which are the most 
common causes of haematuria (Fernandes, et al, 2012). This is because the female urethra 
is shorter and straighter, and closer to the anus (and gut flora) compared to males, hence 
the increased occurrence of urinary tract infection in women. This frequency of UTI/cystitis 
may result in failure to appropriately investigate females, resulting in delayed diagnosis 
(Watkins, 2007; Johnson, et al.2008). In view of this potential to under- or misdiagnose 
females, Kelly, et al. (2009) contends that urinalysis should only be performed after 
menstruation has finished. 
Although haematuria is more common in the elderly (particularly males, over 60 years) than 
in the young, it is important to gather clues as to the underlying cause of the haematuria, 
for example, loin pain suggests renal origin; colicky pain indicates stones/calculi; and 
painless haematuria may indicate a tumour (Ng et al., 2012). Visible haematuria conveys a 
higher risk of urological malignancy (14.7%-21.8% of cases) compared with non-visible 
haematuria (2% - 11% of cases) (O’Regan et al, 2009), although the additional factors of 
positive smoking history, age >40 years, previous malignancies and occupational exposure 
to rubber, dyes and chemicals, significantly increase the risk of developing bladder cancer. 
Although, when these risks are eliminated or reduced, for example, following the removal of 
aromatic amines from dyes, bladder cancer incidence decreases (Christiani, 2011). 
The aim of this paper is to outline the tests and investigations that are undertaken once a 
patient is referred to a haematuria clinic, and to discuss the role of the nurse in supporting 
the patient and improving patient satisfaction. 
 
Referral  
To balance the need for unnecessary investigations, Loo, et al. (2009) recommend urgent 
referral for specialist opinion or investigations for all male and female patients with visible 
haematuria on a single urinalysis, irrespective of age (and irrespective of whether anti-
coagulants or anti-platelet therapy is present). For those experiencing non-visible 
haematuria, both asymptomatic and symptomatic patients should be referred if they 
provide at least two of three positive urinalysis tests, again, irrespective of age. This is in line 
with the referral criteria by NICE (2005) for suspected cancer and follows the ‘two week 
wait’ directive within Primary Care (Department of Health, 1997).   
 
Despite previous research showing evidence for unequal referral patterns for the urological 
evaluation of haematuria (Johnson et al, 2008) the NICE guidelines do not discriminate 
between genders. Patients with haematuria need to be monitored and reviewed from a 
medical and economic perspective (Mostafid et al, 2010), with investigations being specific 
and accurate to prevent over-investigating, avoid under or misdiagnosing cancer,whilst 
simultaneously maximising patient satisfaction and reducing patient anxiety. 
 
Investigations 
Once the patient has been referred to the haematuria clinic, patients will undergo a series 
of investigations (refer to Figure 1 and Table 1). 
 Insert Figure 1 
 
Insert Table 1 
 
Within both referral and initial investigations, the patient will be asked to provide their 
background history (see Table 2), to identify possible causes of haematuria. 
Insert table 2 
At the clinical visit, the potential causes, along with any associated risk factors, will be 
established. Patients will be informed of the range of causes of haematuria, for example, 
some foods (e.g. beetroot) can indicate the presence of blood, but this is ‘normal’ 
discolouration of the urine. These samples would create ‘false positive’ results where a test 
incorrectly indicates a positive result, but the disease is not present.  Normally, the cause of 
these cases is not serious or does not require further investigation. 
For most patients however further tests will be needed. Local policies and corresponding 
investigation protocols may dictate the tests which patients receive (Loo et al, 2009).  It is 
important that the rationale for each test is given to the patient, as well as explaining what 
the test may (or may not) indicate, and which further investigations may be required. 
Patients should also be advised that not all tests will show urological or renal pathology and 
a negative result does not always mean absence of disease.  
Blood tests 
Blood profile (full blood count) is needed to detect the presence of anaemia, and serum 
urea, creatinine and electrolytes are needed to identify any renal impairment (Miah and 
Catto, 2010). If there is evidence of a declining glomerular filtration rate (GFR) (by 10ml/min 
at any stage within the previous 5 years or by >5ml/min with the last year) and if 
urea/electrolyte/creatinine indicate stage 4 or 5 kidney disease, a referral to a nephrologist 
will be needed (BAUS/AR, 2007). 
Urine tests 
Urinalysis: As the primary test for detecting blood in the urine, urinalysis involves the 
patient voiding a fresh sample into a sterile urine pot.  Using a chemical reagent strip, an 
array of tests can be performed to measure the presence of cells and substances, such as 
haemoglobin, protein (which can indicate renal disease), nitrites (which can indicate the 
presence of infection) and pH levels are assessed.  The strip is fully immersed into the urine 
and placed on a dry surface, allowing the test results to develop and appear as colour 
changes on the strip (Steggall, 2007). Urinalysis is a test frequently performed in G.P 
practices, as well as both Outpatient and Inpatient clinical services as a screening test, and 
Nurses must be competent in conducting urinalysis, as well as interpreting, reporting and 
explaining findings of this test. 
-Urine Cytology: The urine will also be used in cytological (cell) analysis, by sending the 
sample for microscopy, culture and sensitivity (Nash, 2010).   Cells passed out of the bladder 
in the voided sample can be used to exclude UTI and detect inflammation or urothelial 
cancers.  The sample is processed in a laboratory and examined under the microscope to 
look for abnormal cells. The use of cytology testing is diminishing however, following several 
reviews stating its sensitivity is too low (Blick, et al, 2011). A new test, the 
NMP22®Bladderchek® test, has been found to be a quicker and cheaper alternative, and its 
use is becoming more prevalent. Potentially, this test can detectmore urological tumours at 
an earlier stage by identifying elevated levels of nuclear matrix protein 22, which exist in 
high levels in cancer cells (Turner, 2008). 
Investigation of the Upper Urinary Tract 
Imaging is used to detect upper tract pathology (Mostafid, et al. 2010), specifically a KUB 
(Kidneys, Ureter and Bladder) Radiographic test (X-ray and / or Renal Ultrasound scan) to 
obtain images of the abdomen.  These diagnostic tests seek to identify gross abnormalities, 
such as kidney stones and gastrointestinal disorders. Although both tests require minimal 
patient preparation and aftercare, radiographic imaging involves minor exposure to 
radiation and so is not suitable for pregnant women. 
Ultrasonography is however a relatively cheap, quick and harm-free investigation that 
involves only light, direct pressure to the skin and requires simple bladder filling for pelvic 
scanning (Malik, 2008). This procedure can identify cystic renal lesions, larger renal tumours 
and is used for testing renal morphology and structure. However, ultrasound may fail to 
identify small lesions, and in these situations further investigation may be required with an 
X-ray of the Urinary system (Intravenous Urography or IVU). However IVU can also fail to 
diagnose small renal or bladder masses, or other causes of haematuria such as calculi. 
McDonald, et al. (2006) contends that the only reliable way of detecting bladder cancer is 
via the lower urinary tract, by flexible cystoscopy.  
 
Investigation of the Lower Urinary Tract 
- Cystoscopy: A long, flexible tube (cystoscope) is inserted into the urethra and enables 
visualisation of the bladder. Cystoscopy is undertaken by an appropriately qualified 
practitioner and is performed under local anaesthesia (using a local anaesthetic and 
antibacterial gel), and can be done on an Outpatient basis or in a Urology clinic. Although 
pain and discomfort are commonly reported by the patient during this procedure (Soomro, 
et al. 2010), research has shown this can be minimised through pre-operative active patient 
involvement and counselling.  Clements et al, (2004) outlined the patient benefits of 
encouraging visualisation of their flexible cystoscopy, which can lead to lower anxiety and 
pain, compared to patients who did not visualise their procedure. 
Should any test/s identify an abnormality or the patient be considered high risk (including 
those aged > 50 years, have a history of smoking and / or occupational exposure), further 
investigations will be necessary to enable a more detailed assessment and minimise any 
false positives or negatives (Blick, et al. 2011). For example, Computerised Tomography (CT) 
may be used to image the entire urinary tract to detect upper tract pathology, due to their 
high sensitivity (Albani, et al. 2007). 
 
Treatment and Follow-up 
In patients whose results are suspicious or a tumour is confirmed, local guidelines will 
dictate how patients should be followed-up. For superficial (non-muscle invasive) tumours, 
a patient will be typically referred for a repeat blue-light cystoscopy, using highly sensitive 
photodynamic detection (PDD) to improve identification and diagnosis.To remove 
superficial tumours, patients will undergo a surgical procedure known as a TURBT (Trans 
Urethral Resection of the Bladder), whereby any unusual growth is removed from the 
bladder wall. To prevent progression, and in conjunction with surgery, additional therapies 
such as BCG (Bacillus Calmette-Guerin) intravesical therapy (a vaccination) or mitomycin C 
(chemotherapy) will be given.  
 
For more aggressive tumours of the bladder (i.e. muscle invasive cancer) suitable patients 
will be given chemotherapy to shrink the cancer, followed by either radiotherapy or surgery.  
Current radiotherapy aims to maximise the delivery of radiation to tumour tissue, whilst 
minimising that to healthy tissues.   
 
When the tumour is advanced and invasive, or if the patient has had repeated recurrence of 
non-muscle invasive cancer, a cystectomy may be required. This is the surgical removal of all 
or part of the bladder, with the formation of an ileostomy (if the entire bladder is removed).   
 
Once treatment is complete, the patient will receive regular follow-up appointments to 
monitor their health status, due to the high risk of recurrence in bladder cancer.  A typical 
follow-up plan includes repeated physical examination, blood tests, urine cytology and 
imaging tests, as well as regular cystoscopy (assuming the bladder has not been removed).  
Any recurrence of haematuria would warrant further/repeat investigation. 
 
Support for Patients  
Irrespective of the investigations that the patient undergoes, recommendations for lifestyle 
changes may be appropriate along their journey to minimise, or if possible prevent, any 
current or future risks to the patient’s health.   
 
Treatment, combined with a diagnosis of any condition associated with haematuria, can 
involve symptoms and side effects, as well as being physically exhausting and emotionally 
stressful for the patient. The focus of healthcare is to provide compassionate and sensitive 
care based around six values, the ‘Six C’s’ care, compassion, courage, communication, 
competence and commitment (Department of Health, 2012), and to deliver compassionate 
care, patients will need the opportunity to talk and raise concerns that they might have. It is 
important that patients feel listened to, understood and actively involved with their care 
(Gourdji, et al.2003). 
Conclusion 
There are two types of haematuria, visible (VH) and non-visible haematuria (NVH), with the 
latter category divided in to symptomatic (s-NVH) and asymptomatic haematuria a-NVH). All 
episodes of haematuria require investigation (to exclude non-urological causes, e.g. 
ingestion of foods that colour urine, as well as UTIs). For individuals with VH, s-NVH (in the 
absence of UTI or other transient causes) and persistent a-NVH, referral to a haematuria 
clinic is needed. At the clinic, causes of haematuria will be investigated using a variety of 
methods, including radiography and cystoscopy. Once the cause has been identified, further 
management can be provided by the Urology or Nephrology team. In the absence of clinical 
findings, patients will require long term monitoring by the primary care team. If VH or renal 
function develops, re-referral back to the haematuria clinic will be required.  
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Figure 1:  An Investigatory Flowchart for patients referred to the Haematuria clinic 
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Intravenous urogram 
Procedure Purpose Advantages Disadvantages 
Urinalysis Detection of 
haemoglobin from a 
urine sample, using 
chemical reagent 
strips 
- Effective: 65-95% specific 
- Inexpensive, convenient 
-Requires minimal training 
- Does not require presence of 
intact blood cells 
- Limited in confirmation of true 
micro-haematuria 
Cytology Examination of urinary 
cells from a urine 
sample, under the 
microscope 
- Non-invasive 
- Can detect Carcinoma in Situ 
(CIS) and high grade 
Transitional Cell Carcinoma 
(TCC) 
-Expensive 
-Poor sensitivity 
-Poor positive predictive value of 
8% 
-Delays the haematuria pathway 
Cystoscopy Visual examination of 
the lower urinary tract 
-  bladder via the 
urethra using a 
cystoscope 
 
- Fundamental Urological 
technique  
- “Gold standard of bladder 
cancer detection” 
-Invasive 
- Expensive 
-Causes pain, discomfort and 
anxiety to patient 
- Does not provide 100% 
sensitivity; superficial bladder 
cancer is rarely found on physical 
examination 
- Enhances the risk of developing a 
urinary tract infection (UTI) by 10% 
- Complications of perforation and 
bleeding possible 
Ultrasonography Diagnostic imaging of 
the upper urinary tract 
using an ultrasound 
- Cheap and Effective 
- Adequately sensitive for 
screening renal and bladder 
abnormalities 
- Avoids radiation exposure 
- Requires minimal 
preparation in terms of fasting 
and bowel preparation 
- Can be conducted on an 
Outpatient basis  
 - Additional investigatory route 
adds to haematuria diagnostic 
pathway 
Table 1: Diagnostic tests for Haematuria (Albani et al, 2007; Malik, 2008; Rao and Jones, 2008; 
O’Regan et al, 2009; Soomro, et al, 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Background Information Rationale 
Age  Haematuria is more common in the older adult. Potential diagnoses 
include bladder cancer, prostate cancer, etc. 
Sex Females have an increased risk of haematuria due to Urinary Tract 
Infections (UTIs) and menstruation. 
Occupation Occupational exposure to dyes, rubbers, textiles and chemicals 
have found to be associated with bladder cancer. 
Family history An onset of persistent microscopic hematuria, typically during 
childhood is indicative of “familial haematuria;” a group of genetic 
kidney disorders for example. 
Medical History For example, a history of previous urological conditions may 
indicate recurrence. 
Physical Activity 
 
Vigorous exercise, mild trauma or sexual intercourse can all be a 
cause of transient haematuria.  
Diet Foods such as beetroot, blackberries and rhubarb can cause urine 
to look red or brown. 
Medication Haematuria may be drug-induced, by non-steroidal anti-
inflammatory drugs, antibiotics or anticoagulants. 
Smoking history Smoking significantly increases the risk of bladder cancer and 
subsequent likelihood of haematuria. 
Drug use Ketamine dependence for example is associated with urinary tract 
effects. 
Haematuria history Number and type of episodes of haematuria, associated pain, 
urological symptoms, and point in the urinary stream when the 
haematuria is visible, will all enable the clinician to help identify 
potential causes 
Table 2: Information required for the Haematuria Patient’s History (Adapted from Turner, 2008; 
Nash, 2010). 
